Relcovaptan
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
Synonyms | (2S)-1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indole-2-carbonyl]pyrrolidine-2-carboxamide |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C28H27Cl2N3O7S |
Molar mass | 620.501 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1a subtype.[1] It has shown positive initial results in tests against Raynaud's disease, dysmenorrhoea, and tocolysis,[2] although it is not yet approved for clinical use.
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.